Phase 1b clinical studies in F1-F3 NASH patients with FIR, an allosteric liver-targeted inhibitor of both ACC isoforms (ACC1 and ACC2), demonstrated a reduction in hepatic fat content and markers of liver injury [31, 54]. The gene discussed is ACACA; the disease is metabolic dysfunction-associated steatohepatitis.